Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.
The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.
Rallybio Corp (RLYB) director Helen M. Boudreau exercised options to acquire 2,062 common shares at an exercise price of $15.28 per share on October 16, 2026. The reported option position had zero shares remaining after the exercise. Her directly held common-stock position was 8,604 shares afterward.
Rallybio Corporation is seeking approval for its proposed merger with Avenzo, with registration covering approximately 193,644,387 Rallybio common shares and options to purchase 19,136,431 shares, before the proposed reverse stock split. Avenzo would survive as a wholly owned subsidiary, and Rallybio would take the name Avenzo Therapeutics, Inc. The assumed exchange ratio is 0.5020, subject to adjustment based on Rallybio Net Cash and shares outstanding at closing.
Avenzo agreed to sell shares for an aggregate purchase price of $215.0 million immediately before the merger’s effective time, subject to closing conditions. After closing, pre-merger Avenzo equityholders other than financing investors are expected to own 56.6% of the combined company, Rallybio’s pre-merger equityholders 2.8%, and financing investors 40.6%; these fully diluted estimates assume $215.0 million in financing and are subject to adjustment.
Rallybio calculated net cash of approximately $82.2 million as of August 15, 2026, and intends to distribute substantially all of it to pre-closing stockholders under the merger agreement. Only one distribution may be declared before the stockholder meeting, capped at $50 million in aggregate. The merger is conditioned on approval of three stockholder proposals and Nasdaq listing confirmation; the annual meeting is scheduled for November 4, 2026.
Rallybio registered approximately 193,644,387 shares of its common stock before the proposed reverse stock split. The prospectus separately identifies 19,136,431 shares reserved for issuance upon conversion of stock options. Under the proposed merger, Merger Sub would merge into Avenzo, which would survive as Rallybio’s wholly owned subsidiary, and Rallybio would change its name to Avenzo Therapeutics, Inc. Eligible Avenzo capital stock would convert into Rallybio shares at an assumed exchange ratio of 0.5020, subject to adjustments based on Rallybio Net Cash and the final number of Rallybio shares outstanding.
Avenzo has agreed to sell common stock for $215.0 million immediately before the merger’s effective time; the financing is conditioned on satisfaction or waiver of merger closing conditions and other conditions. On a pro forma, fully diluted basis, Avenzo pre-merger holders other than financing investors are expected to own 56.6% of the combined company, Rallybio pre-merger holders 2.8%, and financing investors 40.6%. Rallybio estimated Rallybio Net Cash of approximately $82.2 million as of August 15, 2026, and intends to distribute substantially all of it to pre-closing stockholders, up to the amount by which Rallybio Net Cash equals or exceeds $0; distributions may be paid after closing.
Rallybio Corp (RLYB) director Robert Lorne Hopfner exercised three options on October 12, 2026, acquiring 14,820 common shares. The options covered 9,196 shares at an exercise price of $7.60 per share, 3,562 at $2.38, and 2,062 at $15.28. All three options were issued or granted under Rallybio’s 2021 Equity Incentive Plan. The 9,196-share option was issued in lieu of $51,500 in retainer fees.
Rallybio Corp (RLYB) reported that Chief Financial Officer Jonathan I. Lieber exercised options on October 9, 2026, acquiring 3,910 common shares at $6.08 per share. His reported common-share holdings following the transaction were 13,650 shares, and the reported option position following the exercise was zero shares. The option was granted under the Company's 2021 Equity Incentive Plan and vests in 48 equal monthly installments, reaching full vesting on February 14, 2029.
Rallybio Corp's Chief Executive Officer, Stephen Uden, exercised options to acquire 22,456 shares of common stock on October 6, 2026, at an exercise price of $6.08 per share. His reported direct common-stock holdings following the transaction were 115,620 shares.
Rallybio is registering approximately 193,644,387 common shares for its proposed merger with Avenzo, plus 19,136,431 shares reserved upon conversion of stock options. These estimates exclude the proposed reverse stock split and dilution from Avenzo equity issued after May 31, 2026 and before closing. Avenzo would survive as a wholly owned Rallybio subsidiary, and Rallybio would be renamed Avenzo Therapeutics, Inc. Completion depends on stockholder approvals and other conditions.
Avenzo agreed to sell shares to investors for $215.0 million immediately before the merger’s effective time, subject to conditions. Fully diluted ownership is estimated at 56.6% for Avenzo’s pre-merger holders excluding financing investors, 2.8% for Rallybio’s pre-merger holders and 40.6% for financing investors; the estimates are subject to adjustment. Rallybio estimates $82.2 million in Rallybio Net Cash as of August 15, 2026, and intends to distribute substantially all of it to pre-closing stockholders, potentially after closing. Parent Distributions declared before the stockholder meeting are capped at $50,000,000 in aggregate. Nasdaq confirmation of listing approval for the combined company is a merger condition.
Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options covering 5,000 shares on September 29, 2026, at an exercise price of $6.08 per share, and acquired 5,000 common shares. He reported 9,740 directly held common shares following the transaction. The option was granted under Rallybio's 2021 Equity Incentive Plan and vests in 48 equal monthly installments until fully vested on February 14, 2029.
Rallybio Corp (RLYB) director Hui Liu exercised options to acquire 3,562 and 8,482 common shares on September 24, 2026, at exercise prices of $2.38 and $7.60 per share, respectively. The corresponding common-stock entries report acquisition of those same share amounts. The 8,482-share option was issued under Rallybio’s 2021 Equity Incentive Plan in lieu of $47,500 in retainer fees.